8-K

CTI BIOPHARMA CORP.

Date: October 13, 2022

/s/ David H. Kirske

David H. Kirske

Chief Financial Officer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 10, 2022

CTI BIOPHARMA CORP.

(Exact name of registrant as specified in its charter)


Delaware	000-28386	91-1533912
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Number)

3101 Western Avenue, Suite 800

Seattle, Washington 98121

(Address of principal executive offices)

Registrant’s telephone number, including area code: (206) 282-7100

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	CTIC	Nasdaq Capital Market

☐ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 10, 2022, CTI BioPharma Corp. (the “Company”) eliminated the position of Chief Operating Officer. Accordingly, Bruce Seeley resigned as Chief Operating Officer, effective as of that date. In connection with his separation from the Company, Mr. Seeley will be entitled to payment of severance benefits pursuant to his severance agreement with the Company (filed as Exhibit 10.11 to the Company’s Form 10-K for the year ended December 31, 2015). The Company wishes to acknowledge Mr. Seeley’s contributions to the approval and launch of VONJO^® and is supportive of his pursuit of senior leadership opportunities.

As the commercialization of VONJO transitions from the initial launch phase, Jim Fong, the Company’s Chief Commercial Officer, has been promoted to Executive Vice President and Chief Commercial Officer, and will begin reporting directly to the Company’s Chief Executive Officer. The management functions of the former Chief Operating Officer role have been reassigned to other members of the senior management team.

* * *